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Abstract: Mobilizing the research ecosystem for accelerating vaccine and drug development has been an important reality of the
pandemic. This article reviews the scientific advances that are attained by the COVID-19 Turkey Platform for vaccine and drug
development against the SARS-CoV-2 virus. The platform that is coordinated by the Scientific and Technological Research Council
of Turkey is established with a “co-creation and succeeding together” approach, which involves 436 researchers across 49 different
institutions working on 17 vaccine and drug development projects in total. Recent advances of the COVID-19 Turkey Platform include
the fourth virus-like particle-based vaccine candidate in the world to enter clinical studies based on the World Health Organization
COVID-19 vaccine tracker that is currently completing phase 2 clinical studies on the path towards initiating phase 3 clinical studies.
Moreover, an adjuvanted inactivated vaccine candidate and two drug candidates that have been identified through the virtual scanning
of more than 20,000 molecules are currently in clinical studies. Other vaccines and drug candidates involve additional innovative
aspects, and a locally synthesized drug is found to have an impact on COVID-19. This review article discusses the advances that are
achieved by the COVID-19 Turkey Platform from the ecosystem perspective, emphasizing the important scientific advances that have
been achieved in the field of medical sciences.
Key words: Vaccine, drug, COVID-19, SARS-CoV-2, co-creation

1. Introduction
Mobilizing the ecosystem to strengthen the vaccine and
drug development value chain against the COVID-19
pandemic has been imperative to have a positive impact
on a healthy society. About one and a half months before
the declaration of COVID-19 as a pandemic by the
World Health Organization (WHO) [1], the first meeting
that would lead to the development of vaccine and drug
candidates was held in Turkey under the leadership of the
Ministry of Industry and Technology [2]. This initiative
led to the launch of the COVID-19 Turkey Platform for
vaccine and drug development that is coordinated by the
Scientific and Technological Research Council of Turkey
(TUBITAK). A total of 436 researchers from 49 different
institutions have taken part in the COVID-19 Turkey
Platform, which has further expanded among professionals
who have supported the production processes and clinical
studies of the developed candidates, representing a great
mobilization of the ecosystem.
Since its initiation, the COVID-19 Turkey Platform
has been established based on the approach of “cocreating and succeeding together”, which has become an

important approach for the achievement of the platform.
The role of the COVID-19 Turkey Platform in mobilizing
the ecosystem to achieve a positive impact based on
vaccine and drug development against the pandemic was
represented in earlier studies [3,4]. The unique platform
has continued an intense and focused dedication to the
sharing of resources, including human resources, as
well as research infrastructure. This implementation has
accelerated R&D processes with a focus on co-creation
as a common approach. As summarized in Figure 1,
the researchers who implemented the research projects
have involved 118 researchers from higher education
institutions, 67 researchers from public R&D institutes and
units, 38 researchers from the private sector, and 213 young
researchers, including 167 holders of STAR scholarships.
The direct involvement of an important share of young
researchers has supported the approach of the platform
while ensuring its sustainability. The developments of the
COVID-19 Turkey Platform were shared transparently
in virtual conferences with public presentations [5,6].
There has been additional sharing of developments in an
online portal, namely the COVID-19 Data Portal Turkey
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Figure 1. Representation of the co-creation based approach of the COVID-19 Turkey Platform.

[7] that is associated with the European COVID-19 Data
Portal [8], and periodic sharing of the most recent updates
through public interviews. In addition to the responsibility
of the COVID-19 Turkey Platform to the local ecosystem,
the platform has broader international visibility with its
being recognized as a model for co-creation based scientific
approaches at the international level.
At the global level, an assessment, which was conducted
eleven months after the rise of the SARS-CoV-2 virus,
identified nearly 300 vaccine projects that were being
focused in the scientific community, including new
technologies [9]. The basic scientific approach in the SARSCoV-2 virus characterization, including the structural
glycoproteins and the domains of the Spike protein, has
guided this process. At the same time, the overwhelming
majority of vaccine candidates have focused on targeting
the Spike protein. On the other hand, a more comprehensive
vaccine design strategy can provide important advantages
against certain instability challenges, especially during the
mutation process.
A recent update in the COVID-19 vaccine tracker and
landscape of the WHO indicated a total of 292 vaccine
candidates as of July 27, 2021 [10]. The Sankey diagram in
Figure 2a indicates the flows among the different vaccine
technologies based on the 108 vaccines in the clinical
stages and 184 vaccine candidates in the pre-clinical stages
as of July 27, 2021. As observed from the Sankey diagram
in Figure 2a, the largest number of vaccine candidates is
related to the protein subunit type, including recombinant
Spike protein, which represents 33% of the total number of
vaccine candidates in clinical studies and about 39% of the
total number of vaccine candidates in pre-clinical studies.
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RNA based vaccine candidates, which is composed of
17% of the total number of vaccine candidates in clinical
studies and 13% of the total vaccine candidates in preclinical stages, form the next category having the second
largest number of vaccine candidates. Viral vector-based
vaccines are reported based on the non-replicating (VVnr)
and replicating (VVr) types in consistency with the data
source [10]. As observed from Figure 2b, there are 5 viruslike particle (VLP) vaccine candidates in clinical studies,
which represents about 5% of the total number of vaccine
candidates in clinical studies. The distribution of vaccine
candidates in pre-clinical studies are further represented
in Figure 2c. In total, there are 23 VLP vaccine candidates
either in clinical or pre-clinical studies in the world, which
represents only 8% of the existing vaccine candidates in the
scope of either stage.
2. Vaccine candidates of the COVID-19 Turkey Platform
A very important transformation was achieved with the
approach of “co-creation and succeeding together” in the
7 vaccine development projects of the COVID-19 Turkey
Platform. All of the different vaccine technologies that are
being used across the world have been brought together
in a single platform and brought to a higher level through
adding new features to create innovative vaccine candidates
of the COVID-19 Turkey Platform. This mobilization has
strengthened the process of designing, developing, and
producing innovative vaccine candidates under the strong
pressure of the pandemic. Having been used to develop
innovative vaccine candidates, these technologies of the
COVID-19 Turkey Platform have been designed and
developed to include important features in terms of efficacy.
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The low percentage of VLP candidates in the total
number of vaccine candidates against COVID-19 in the
world as observed above in Figure 2 can be attributed
to the fact that the development of this type of vaccine
candidates can be technically challenging. In contrast
to the technical challenges, VLP vaccine candidates can
present important benefits, including good safety profiles,
since the formulation does not include the genetic material
of the pathogen [11]. Instead, the VLP vaccine candidates
mimic the structure of the virus for the purpose of
triggering a strong immune response.
The VLP vaccine candidate of the COVID-19 Turkey
Platform mimics a non-infectious form of the SARSCoV-2 virus. In addition, the design of this innovative
vaccine candidate of the COVID-19 Turkey Platform
targets four structural proteins based on the Spike protein
as well as the Membrane, Nucleocapsid, and Envelope
proteins (M, N, E). In this scope, it is recognized that
the VLP technology has not been tested in any vaccine
platform with the expression of these proteins together.
The VLP vaccine candidate of the COVID-19 Turkey
Platform is developed by design to provide immunization
against the SARS-CoV-2 virus. The immunization range
of the VLP vaccine candidate has also been increased
by using an adjuvant that is licensed for safe for human
use. Previously, a research team, including the scientists
who developed this vaccine candidate had discovered
that immune adjuvants can be improved through the
inclusion of CpG. In particular, the use of synthetic
oligodeoxynucleotides (ODNs) that contain unmethylated
motifs of CpG was reported to promote the production of
Th1 helper cells and pro-inflammatory cytokines, thereby
increasing vaccine-induced immune responses [12].
Various studies had also reported the positive effect of
CpG, including boosting immunity with antigen-specific
responses [13] and improving the activity of vaccines with
a good safety profile that target infectious diseases [14].
These important findings have been integrated into the
VLP vaccine candidate as additional benefits beyond its
targeting of the four structural proteins.
With these innovative features, the VLP vaccine
candidate of the COVID-19 Turkey Platform has become
the fourth vaccine candidate in the world to enter clinical
studies based on the WHO vaccine tracker within a few
weeks after March 27, 2021. More specifically, the Phase
1 clinical study of the VLP vaccine candidate of the
COVID-19 Turkey Platform has been undertaken and
registered with identifier NCT04818281 [15]. The study
involved 36 participants with randomized allocation
and double-blind method that has been administered
as two injections subcutaneously in a low dose at 10 µg
(12 participants), a high dose at 40 µg (12 participants)
as well as a placebo group. The Minister of Industry
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and Technology and the President of TUBITAK were
volunteers in this first human clinical trials of the VLP
vaccine candidate of the COVID-19 Turkey Platform [16].
The Phase 2 clinical trial of the VLP vaccine candidate of
the COVID-19 Turkey Platform that initiated on June 26,
2021 has been conducted as a randomized, double blind,
and multi-center clinical study across three different
clinical centers in Ankara, İstanbul, and Kocaeli [17], and
the efficacy, safety, and immunogenicity of the VLP vaccine
have been assesed. This study included 330 participants
and involved the original VLP vaccine that was developed
for the Wuhan variant as well as another design that was
developed against the Alpha (British) variant. Two groups,
each composed of 110 participants, have received the first
and second doses of either the original VLP vaccine or
Alpha variant VLP vaccine versions. In addition, another
110 participants have been administered with one dose
of each design 21 days apart. The clinical study involved
volunteers aged between 18 and 59, and they were
registered with the ID: NCT04962893 [18].
When compared to the information given in the
most recent version of the WHO vaccine tracker, there
is only one other VLP vaccine candidate that is in Phase
2/3 trials [19]. Two other VLP vaccine candidates are in
Phase 1/2, and another is in Phase 1 clinical trials. The
relevant clinical studies of VLP vaccine candidates are
summarized in Table [10]. The developers are given in
[10] with the VLP vaccine candidate in the first row as the
VLP vaccine candidate of the COVID-19 Turkey Platform
coordinated by TUBITAK. The Delta (Indian) variant of
the SARS-CoV-2 virus will be also integrated in the Phase
3 studies of the VLP vaccine candidate of the COVID-19
Turkey Platform, which is a strong indicator of the strong
research competency of the ecosystem. As of July 2021, the
VLP vaccine candidate is completing the administration
of second doses under Phase 2 studies while preparing
for Phase 3 clinical trials that will also include the Delta
variant. The candidate has the potential also to address
international needs.
As another innovative candidate, the inactivated
vaccine candidate of the COVID-19 Turkey Platform
is developed to have advantageous qualities in terms of
safety and efficacy. The advantageous features are obtained
based on the contents that support the formulation of the
inactivated vaccine candidate. As an advantage of working
together in a collaborative platform with the approach of
“co-creation and succeeding together”, it was observed
that the highest antibody response is obtained when
CpG is added to the aluminium hydroxide or Al(OH)3
adjuvant used in inactivated vaccines, which are the ones
produced by the traditional vaccine technology. For this
reason, an innovative feature of this candidate is the use
of the Al(OH)3+CpG adjuvant within the formulation of
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Table. Clinical study registrations of VLP vaccine candidates against COVID-19 [10].
VLP Vaccine
Candidates

Phase 1

1

NCT04818281

2

NCT04450004

Phase 1/2

Phase 2
NCT04962893
NCT04662697

3

NCT04773665

4

ACTRN12620000817943

5

Phase 2/3

NCT04636697

NCT04839146

the vaccine candidate. The Phase 1 clinical studies of the
adjuvanted inactivated vaccine of the COVID-19 Turkey
Platform are conducted with 50 participants who are
aged between 18 and 45, and they were administered in
two different doses. In the clinical study, 40 participants
received doses that included 10 µg-3M inactivated virus
or 20 µg-6M inactivated virus alongside 1 mg Al(OH)3
and 300 µg CpGODN adjuvanted vaccine, while 10
participants took place in the placebo group. After the
administration of doses, which have been registered with
identifier NCT04866069, in Phase 1 clinical studies [20],
preparations towards the initiation of Phase 2 clinical
studies of the inactivated vaccine are in the process of
completion.
Overall, the COVID-19 pandemic has accelerated the
development of new types of vaccine platforms, including
viral vector-based vaccines and mRNA vaccines [21] that
are further represented in the COVID-19 Turkey Platform.
The adenoviral vector vaccine candidate of the COVID-19
Turkey Platform is a viral vector-based vaccine that is
designed to broadly recognize the antigens of the SARSCoV-2 virus and to provide a strong and long-lasting
immunity against them. It is also recognized that viral
vector-based vaccine candidates can be successful vaccine
technologies for creating a strong immune response to
prevent the spread of the virus. In comparison to other
adenoviral vector-based vaccines that are developed
against this virus, the vaccine candidate of the COVID-19
Turkey Platform takes place as a second-generation
vaccine that has a new design. Following the process
of the development of VLP and adjuvanted inactivated
vaccine candidates of the COVID-19 Turkey Platform, the
adenoviral vector-based vaccine is planned to become the
third vaccine candidate to initiate clinical studies.
Two other types of vaccine technologies provide an
important level of flexibility for manipulating the coded
antigen with rapid speed, namely the DNA and mRNAbased vaccines [9]. In the COVID-19 Turkey Platform, the
DNA vaccine candidate is developed and is being produced
at pilot scale based on Good Manufacturing Practice
(GMP) for proceeding into clinical studies similar to the

other vaccine candidates. Moreover, the mRNA based
vaccine technology has gained a remarkable momentum
during the COVID-19 pandemic [22]. The mRNA vaccine
candidate that is being developed under the COVID-19
Turkey Platform is designed to be stable for 6 months at
room temperature. The thermostable characteristic of the
vaccine candidate is expected to provide an important
advance. Moreover, recombinant viral protein technologies
are known to provide protective efficacy; the effect of the
recombinant vaccine against the hepatitis B virus infection
is one of the major example regarding this efficacy [23].
Among the other vaccine technologies, the recombinant
Spike protein vaccine candidate is being developed in
the COVID-19 Turkey Platform with advances towards
clinical studies.
Another important innovation within the COVID-19
Turkey Platform is the development of the ASC particle
technology based COVID-19 vaccine candidate. The
apoptosis-associated speck-like (ASC) protein that is
naturally present in human cells can spontaneously form
particles when certain conditions are met. The formation
of ASC particles is being used in the vaccine candidate of
the COVID-19 Turkey Platform that is based on the ASC
particle technology and is being developed as a novel
vaccine technology in the world. Previously, processes that
involved a supramolecular complex of the ASC speck were
suggested to have an important role in cytosolic antigen
presentation [24]. The new vaccine candidate has been
progressing successfully towards GMP pilot production.
3. Drug candidates of the COVID-19 Turkey Platform
Within the scope of the COVID-19 Turkey Platform, there
are 10 different treatment-oriented drug development
projects that involve local synthetic drug synthesis and
production, drug molecular modeling, recombinant
neutralizing antibody, and convalescent plasma related
opportunities. Such a range of treatment-oriented drug
development projects is compatible with the range of
treatment opportunities that are being pursued in the
world. In this scope, the COVID-NMA Initiative that
includes the support of WHO aims to provide a dynamic
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mapping and systematic review of COVID-19 studies,
including treatment-oriented drug development studies
[25]. As of July 21, 2021, there were 2542 treatment
oriented studies that were classified based on the type of
pharmacological treatment in the COVID-NMA Initiative
[26]. The distribution of these studies is represented in the
Sankey diagram in Figure 3 with the largest share among
the different types of pharmacological treatment being
antivirals. Studies based on monoclonal antibodies are also
among the top three types of pharmacological treatments
as represented within the COVID-19 Turkey Platform.
Two of the antiviral based pharmacological treatment
opportunities that are represented in this database
are provided by the drug development projects of the
COVID-19 Turkey Platform based on two different
opportunities that have been identified based on the
virtual scanning of over 20,000 molecules. One of these
studies is based on the evaluation of the efficacy and safety
of the use of Favipiravir and Ribavirin in the process of
treating patients diagnosed with COVID-19 within 72 h
[27]. As a guanosine analog that is able to interfere with
the replication process of RNA and DNA viruses [27], the
virtual screening had identified Ribavirin as a promising
candidate that is represented in this clinical study.
Previously, Ribavirin was also used during the outbreak
of SARS in combination with other treatments that have
an anti-inflammatory effect. Most recently, the studies
of the research team of the COVID-19 Turkey Platform
provided a detailed molecular analysis that showed its
inhibitory effect on decreasing the TMPRSS2 enzyme
[28]. The related clinical study is being undertaken with
100 participants with identifier of NCT04828564 [27].
Favipiravir that has been applied successfully for
supporting the treatment of the COVID-19 infection
in Turkey is a result of another important achievement
of the COVID-19 Turkey Platform. The synthesis of the
Favipiravir active ingredient involved a total of eight
steps was synthesized in laboratory and industrial scale
with completely domestic and national capabilities. In
the project, different areas of expertise and production
competencies, from organic chemistry synthesis to
pharmaceutical technology, were brought together and
a licensed pharmaceutical product was presented to
the society through university-industry cooperation.
In the first months of the pandemic on July 10, 2020,
the bioequivalence study for the generic drug was
completed, and its license was obtained. Since then, the
locally synthesized and produced drug that contains the
Favipiravir as active ingredient is being used successfully to
support the treatment of COVID-19. The achievement has
shown the importance of university-industry collaboration
for positive impact. In addition to Favipiravir, the team
has also locally synthesized Hydroxychloroquine and
Remdesivir.
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Based on a drug repurposing approach, another
achievement of the COVID-19 Turkey Platform is
the identification of the Montelukast molecule that is
observed to prevent the SARS-CoV-2 virus from entering
human cells and inhibit the main protease enzyme to avoid
reproduction within the cell [29]. In this way, the agent
is found to demonstrate a dual inhibition profile. The
process of identification was based on virtually scanning
over 15,000 molecules with a special algorithm, and then
biological tests were applied to 25 molecules. Similar
algorithms have been used previously to further identify
multi-target HIV agents in other studies [30]. The project
has benefited from a multidisciplinary approach for
identifying opportunities in drug repurposing studies as
well as the local competence of local drug synthesis. As
a leukotriene (D4) receptor antagonist, Montelukast was
identified as a novel agent that focuses on two important
targets of the SARS-CoV-2 virus [31]. The Phase 2 study
has been initiated with 380 participants that experimentally
compares Montelukast, Montelukast plus Favipiravir and
only Favipiravir as the standard treatment [31]. The two
main studies that have reached the stage of clinical studies
are further represented in Figure 4.
Various compounds and lectins, such as Griffithsin,
have been recognized to be possible inhibitors for
coronaviruses in general, including the severe acute
respiratory syndrome (SARS), Middle East respiratory
syndrome and the avian infectious bronchitis virus [32].
Another achievement of the COVID-19 Turkey Platform
has focused on the Griffithsin molecule in its natural form
for preventing the infection that is caused by the SARSCoV-2 virus. Important progress has been made for the
utilization of the Griffithsin molecule for treatment against
COVID-19 based on its properties for preventing and
avoiding viral replication. Moreover, as proteins protect
the human body against external threats such as viruses
and bacteria, monoclonal antibodies have been identified
as another promising opportunity for the treatment of
COVID-19. Utilizing competences in biotechnological
pharmaceutical drug development based on biosimilar
drug production, existing infrastructure and technologies
were mobilized for antibody-based drug therapy
candidate against the SARS-CoV-2 virus for the treatment
of COVID-19 patients. As another opportunity, Sarseptin
has been developed as a drug candidate for temporary
protection of high-risk groups that may not be vaccinated.
Among anti-inflammatory studies that are relatively
less represented in the pharmacological treatment
candidates in the world (Figure 3), another project of the
COVID-19 Turkey Platform has focused on controlling
and suppressing the inflammatory response. In particular,
the Cytokine storm has been an important source of
concern in the COVID-19 infection, since the severe
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Figure 3. Distribution of different studies including pharmacological treatment candidates [26]. Originally drawn based on
July 21,3.2021
data.
Figure
Distribution
of different studies involving pharmacological treatment candidates [26].

Originally drawn based on July 21, 2021 data.
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in Turkey has been supported with another important achievement of the COVID-19 Turkey Platform.
The synthesis of the Favipiravir active ingredient that involved a total of eight steps was synthesized 3145
in laboratory and industrial scale with completely domestic and national capabilities. In the project,
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Figure 4. Representation of pharmacological studies with a focus on Ribavirin and Montelukast.

“SARS coronavirus”. The results of the mapping of the
key words’ co-occurrences based on article and review
publications in Scopus with authors from Turkey during
the years 2020 and 2021 are summarized in Figure 5. In
total, the mapping of the key word co-occurrences in the
scope of SDG3 and COVID-19 related key words points
out 1612 articles and review papers in total as of July 30,
2021. The color intensity in Figure 5 represents the cooccurrence frequencies.
Figure 5 represents a diverse contribution of scientific
disciplines, including biochemistry, genetics and molecular
biology, agricultural and biological sciences, chemical
engineering, chemistry, computer science, decision
sciences as well as arts and humanities. These scientific
contributions have involved a focus on specific treatment
opportunities, such as Hydroxychloroquine, Remdesivir
and Chloroquine as well as broader keywords based on
immunology and epidemiology. An interactive version is
provided in Supplementary Material. Moreover, the source
of 46 of publications with SDG3 and COVID-19 related
key words is the Turkish Journal of Medical Sciences as the
top journal of publication. The most cited five articles in
this journal have focused on anti-inflammatory treatments
[34], antiviral treatments [35], epidemiology [36],
control measures [37], and pediatric patients [38]. These
contributions are extended in the second special issue of
the Turkish Journal of Medical Sciences that is dedicated to
COVID-19.
The additional contributions in the second special
issue of the Turkish Journal of Medical Sciences that has a
focus on the first year of the COVID-19 pandemic updates
include important evaluations, including those towards
a new wave based on variants and booster vaccinations
[39]. Other contributions have focused on policies during
the pandemic and protective measures [40]. Additional
contributions in recent issues of the Turkish Journal of
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Medical Sciences include a review of COVID-19 related
scientific publications [41] as well as treatment of
COVID-19 patients with Tocilizumab [42] and Favipiravir
[43]. Clearly, the scientific community has been actively
stimulated for COVID-19 research. In addition, TUBITAK
has supported small and medium-sized enterprises in
developing technological solutions, including innovative
diagnostic kits and monitoring systems [44] and reference
materials for RNA based diagnostic kits that were developed
and commercialized in less than three months [45].
Moreover, recognizing that the pandemic has widespread
impacts on society, TUBITAK supported 97 projects in the
social sciences and humanities, including those addressing
education, economics, business, sociology, communication,
architecture, urban and regional planning, psychology,
political science, and public administration. The policy
relevant implications of the impact-oriented projects with
a maximum duration of six months were shared in a virtual
conference with 26 sessions [46] and published in a related
booklet [47]. The role of the social sciences and humanities
for solutions during the pandemic is highly relevant
considering quadruple helix approaches that extends to
society [48].
5. Conclusions for co-creation based approaches for
impact
Advancing solutions against the pandemic has required
an intense mobilization of entire ecosystems that includes
the achievements of the COVID-19 Turkey Platform
for vaccine and drug development. These achievements
have taken place in an ecosystem where “co-creation
and succeeding together” based approaches are being
implemented intensively for impact-oriented solutions,
including those that have an impact against the pandemic
for better health and wellbeing. This review article has
emphasized the achievements of the COVID-19 Turkey
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Figure 5. Mapping of the keyword occurrences of COVID-19 related publications in Turkey Originally drawn by using
July 30, 2021 data.

Platform based on this approach, including the advances
regarding the fourth VLP vaccine candidate in the world
on the path towards initiating its Phase 3 clinical studies.
Moreover, the review article has placed the achievements
on the sides of both vaccine and drug development in the
broader context of progress at the global level based on the
WHO vaccine tracker and COVID-NMA Initiative. The
review article also provided a mapping of the scientific
landscape of publications with SDG3 and COVID-19
related key words in Turkey, as the ecosystem is seeking to
make a positive impact for a healthier society.
The scope of this review article is to benefit a widespread
understanding of these achievements while emphasizing
the transformative role of the pandemic in conducting
and implementing scientific advances based on a “co-

creation and succeeding together” approach. Recently,
opportunities for strengthening science systems in a postCOVID world are addressing similar advances [49]. These
valuable experiences are highly relevant for accelerating
progress towards sustainable development that is
necessary for sustainability-oriented innovation systems
[50] across multiple challenges, including but not limited
to those in the field of medical sciences. Transformations
are being diffused into opportunities for more sustainable
and resilient societies [51], which is gaining importance
every day for a healthy future of human civilization.
Supplementary Material
The file that provides an interactive version of Figure 5 is
attached and can be viewed online [52].
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